Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGE-A3 ASCI +/- Poly IC:LC in Resected Melanoma
NCT01437605Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2011
- Primary completion
- Jul 2018
- Modality
- Antisense DNA, Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of astuprotimut-R, poly iclc in melanoma, sponsored by Moffitt Cancer Center. Started Oct 2011; status: terminated.
02
Drugs
astuprotimut-Rpoly iclc
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01437605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01437605.